Accelerated dissolution testing for controlled release microspheres using the flow-through dissolution apparatus

Pharmaceutical Development and Technology

Volumn 14, Issue 1, 2009, Pages 9-17

  Collier, Jarrod W ^a   Thakare, Mohan ^b   Garner, Solomon T ^b   Israel, Bridg'ette ^b   Ahmed, Hisham ^b   Granade, Saundra ^b   Strong, Deborah L ^b   Price, James C ^b   Capomacchia, A C ^b  

^a HOWARD UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Accelerated flow through dissolution; Flow rate; pH; Temperature; Theophylline

Indexed keywords

MICROSPHERE; SURFACTANT; THEOPHYLLINE;

APPARATUS; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISSOLUTION; DRUG CAPSULE; ELECTRON MICROSCOPE; ELECTRON MICROSCOPY; FLOW RATE; HIGH TEMPERATURE PROCEDURES; PH; PRIORITY JOURNAL; QUALITY CONTROL;

BUFFERS; CAPSULES; DELAYED-ACTION PREPARATIONS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PHARMACOPOEIAS AS TOPIC; SODIUM DODECYL SULFATE; SPECTROPHOTOMETRY, ULTRAVIOLET; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; THEOPHYLLINE; TIME FACTORS;

EID: 61649102436     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802409362     Document Type: Article

References (21)

1. US Pharmacopeia 29. Official monographs, Theophylline. Rockville, MD; 2006:2109-2119.
2. Fotaki A, Reppos C. The flow through cell methodology in the evaluation of intralumenal drug release characteristics. Dissolut. Technol. 2005;5:17-21,23-25.
3. Beyssac E, Lavigne J. Dissolution study of active pharmaceutical ingredients using the flow through appratus USP 4. Dissolut. Technol. 2005;23-25.
4. Glantzman JM, Raton JL. Dissolution tests with the flow-through method. 29 March 2006;1-5. (http://www.pharmaquality.com/mag/112005/pfq-112005-FE2.html) .
5. Miret M, Abrahamase L, de Groene EM. Comparison of in vitro models for the prediction of compound absorption across human intestine. J. Biomolec. Screening. 2004;9:598-606.
6. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the biophamaceutics classification system. Int. J. Pharmaceut. 2006;321:1-11.
7. FDA. The Biopharmaceutics Classification System Guidance. FDA/CDER; 2007.
8. Budavari S, editor. The Merck Index. 12th ed. NJ: Merck & Co. Inc.; 1996. pp 9421.
9. Gennaro AR. Remington's The Science and Practice of Pharmacy 2000. 20th ed. PA: Lippincott Williams & Wilkins; 2000.
10. Zackrisson G, Ostling G, Skagerberg B, Anfalt T. Accelerated Dissolution Rate Analysis (ACDRA) for controlled release drugs. Application to Roxiam® . J. Pharm. & Biomed. Anal. 1995;13:377-383.
11. Quist PO, Ostling G. Accelerated dissolution testing for improved quality assurance. J. Pharm. & Biomd. Anal. 2002;28:1081-1089.
12. Gray VA, Worrell D. Highlights of AAPS in vitro release and dissolution testing focus group. 29 April 2005, Groton, CT. Accessed from the website: http:/www.aapspharmaceutica.com/inside/focus-groups/InVitro/index.asp.
13. Gray VA. Challenges to dissolution testing, including calibration, rebuttal and common ground. AAPS workshop on challenges for dissolution testing for the 21st century. 1-3 May 2006; Arlington, VA.
14. Macheras P, Koupparis M, Apostolelli E. Dissolution of four controlled-release theophylline formulations in milk. Int. J. Pharm. 1987;36:73-79.
15. The Joint Pharmaceutical Analysis Group. Understanding the physical chemistry of modified release systems. Pharmaceut. J. 2006;277(7407):9-20.
16. Shameem M, Lee H, DeLuca PP. A short-term (accelerated release) approach to evaluate peptide release from PLGA depot formulations. AAPS Pharmsci. 1999;1(3) article 7.
17. Rekhi GS, Nellore RV, Hussain AS, Tillman LG, Malinowski HJ, Augsberger LL. Identification of critical formulation and processing variables for metropolol tartrate extended-release (ER) Tablets. J. Controlled Rel. 1999;59(3):327-342.
18. Chowdary K, Rao M, Krishna B. Effect of surfactants on the solubility and dissolution rate of carbamazepine from controlled release Tablets. J. Chem. Sci. 2007;5(3):1306-1310.
19. Nelson DGA, Gallopo A. Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising nonmenthol flavoring. United States Patent and Trademark Office Application #:20060153780; 2006.
20. Neman RL. Physical properties of potassium dodecylsulfate. Texas J. Sci. 1968;20(2):199-205.
21. Goto A, Sakamoto K. Behavior of potassium ions in sodium lauryl sulfate solutions. Yukagaku. 1971;20(9):563-568.